Perspective

Novel approaches for the management of depressive disorders

Manuella P. Kaster [a], Morgana Moretti [b], Mauricio P. Cunha [a], Ana Lúcia S. Rodrigues [a,*]

[a] Department of Biochemistry, Center of Biological Sciences, Federal University of Santa Catarina, Florianópolis, SC, Brazil
[b] Department of Nutrition, Center of Health Sciences, Federal University of Santa Catarina, Florianópolis, SC, Brazil

ABSTRACT

Major depressive disorder is a disabling psychiatric condition that causes a significant burden on individuals and society. There is still a lack of a clear understanding of the neuropathological changes associated with this illness and the efficacy of antidepressants is still far from optimal. Research into antidepressant therapies has evolved from serendipitous observation in human trials, but more than 60 years after the first monoaminergic antidepressants emerged they remain the mainstay for treating depression. However, glutamatergic modulators such as ketamine became the forefront of antidepressant exploration, especially for treatment-resistant depression and suicidal ideation. The glutamatergic hypothesis of depression is not new, however other NMDA receptor modulators do not seem to share the rapid and sustained effects of ketamine, suggesting that a unique combination of intracellular targets might be involved in its effect. Interestingly, inflammation can impact the glutamatergic system enhancing excitotoxicity and decreasing neuroplasticity. The points of convergence between the inflammatory and glutamatergic hypotheses of depression are not completely established, especially regarding the effects of fast-acting antidepressants. In this review, we discuss the most recent research surrounding glutamatergic fast-acting antidepressants, capable of modulating cellular plasticity and synaptogenesis and the potential of anti-inflammatory compounds evaluated from a different perspective. The combination of innovative ideas plus improvements on the discoveries made so far might lead to advances in antidepressant research with the promise of finding compounds that are both effective and fast-acting, even in patients who have tried other therapies with limited success.

© 2015 Elsevier B.V. All rights reserved.

1. Major depressive disorder (MDD) – pathophysiology and current antidepressant treatment

MDD causes profound socioeconomic burden and negative impact on functioning and quality of life of patients (Papakostas and Ionescu, 2015). Although there has been significant research directed towards understanding the biologic underpinnings of MDD, there is not a complete consensus about the neurochemical alterations present in depressive individuals. The monoamine hypothesis of depression proposes that underactivity of monoamines may underlie the pathophysiology of this disorder (Schildkraut, 1965). In addition, impairments on structural plasticity and cellular resilience associated with reduced levels of brain-derived neurotrophic factor (BDNF) have been implicated in the pathophysiology of MDD (Sen et al., 2008). Chronic antidepressant treatment increases BDNF levels, particularly in the hippocampus and prefrontal cortex, leading to stimulation of intracellular signaling pathways and consequent regulation of genes associated with neuroplasticity and cell survival (Castrén and Rantamaki, 2010).

Inflammation has also emerged as an important etiologic factor, and thus a potential pharmacological target for MDD. Pro-inflammatory cytokines are increased in depressed patients (Dowlati et al., 2009) resulting in an imbalance in critical neuroactive compounds and changes in brain structural and synaptic plasticity (Dantzer and Walker, 2014). Interestingly, antidepressant therapy may attenuate this inflammatory dysfunction in depressed individuals (Lanquillon et al., 2000). Moreover, neuroinflammation is associated with increased extracellular glutamate levels, causing neurotoxicity that contributes to depressive symptoms (Sanacora et al., 2012).

Current antidepressant treatments are limited in both efficacy and tolerability. The drawbacks include delayed therapeutic onset and side effects that reduce adhesion to treatment (Papakostas and Ionescu, 2015). Approaches targeting new pathways have been investigated and may represent a significant improvement in

the therapeutic armamentarium for treating MDD.

2. The search for fast-acting antidepressants: targeting the glutamatergic system

Seminal work by Trullas and Skolnick (1990) was the first reporting that NMDA receptor antagonists exhibit antidepressant properties in preclinical models. After this observation, several laboratories demonstrated that functional antagonists at multiple NMDA receptor sites including ligands at glutamate, polyamine, glycine, bivalent cations and ionophore recognition sites are efficacious in models of depression (Sanacora et al., 2012).

In the late 1990s reduction of NMDA receptor function was recognized as a long-term adaptation associated with antidepressant effects (Skolnick, 1999). A promising clinical study by Berman et al. (2000) showed that the non-competitive NMDA receptor antagonist ketamine induced a rapid and persistent antidepressant response in severe depressive patients. Evidence now indicates that ketamine inhibits NMDA receptors on GABAergic interneurons increasing glutamate release. The consequent activation of AMPA receptors causes depolarization of postsynaptic neurons, leading to voltage-dependent calcium channel activation. As a consequence, BDNF released from vesicles activates mTOR signaling. Finally, translation of synaptic proteins in prefrontal cortex, particularly those implicated in synaptogenesis, including PSD-95, synapsin and GluA1 is the final event associated with ketamine's rapid antidepressant effect (Li et al., 2010).

Although the discovery of ketamine for treating severe depressed patients has represented a significant advance in the field, its abuse liability and potential neurotoxicity upon repeated use has led to the interest in the development of safer fast-acting antidepressants (Abdallah et al., 2015). Considering that ketamine modulates the glutamatergic system, there has been increasing interest in targeting this system for the development of novel fast-acting antidepressants.

Our research group has particular interest in antidepressant effects afforded by some endogenous compounds that target the glutamatergic system. Several compounds capable of modulating glutamatergic neurotransmission exhibit antidepressant effects in animal models, such as zinc (Manosso et al., 2015), magnesium (Cardoso et al., 2009), agmatine (Neis et al., 2015), ascorbic acid (Moretti et al., 2011), creatine (Cunha et al., 2015a) and guanosine (Bettio et al., 2012). We showed that ascorbic acid, creatine and guanosine exert antidepressant-like effects by inhibiting NMDA receptors and activating mTOR signaling (Bettio et al., 2012, Cunha et al., 2015a,b, Moretti et al., 2014). The hippocampal phosphorylation of p70S6K, a downstream target to mTOR, and increased levels of PSD-95 were already observed 1 hour after a single administration of ascorbic acid or creatine in mice (Cunha et al., 2015b, Moretti et al., 2014). Moreover, the mTOR inhibitor rapamycin abolished the antidepressant-like effect of ascorbic acid, creatine and guanosine in the tail suspension test (Bettio et al., 2012, Cunha et al., 2015b, Moretti et al., 2014), suggesting that mTOR activation may be a key event underlying the antidepressant effects of these compounds.

Although there is limited clinical evidence indicating the beneficial effects of these compounds for MDD, zinc supplementation was effective in combination with conventional antidepressants (Lai et al., 2012). Regarding magnesium, although it still remains to be established if its administration elicits ketamine-like effects in behavioral paradigms, it is reported that ketamine increases brain magnesium levels (Murck, 2013). A randomized clinical trial showed that magnesium was as effective as imipramine for treating MDD in diabetics (Barragán-Rodríguez et al., 2008). The antidepressant effect of agmatine was documented in a small

number of subjects (Shopsin, 2013) and ascorbic acid was effective as adjuvant agent for MDD in pediatric patients (Amr et al., 2013). Antidepressant effects of creatine supplementation were also reported in depressive patients (Allen, 2012). However, there are no clinical studies evaluating the mood effects of guanosine.

The antidepressant effects of other NMDA receptor antagonists and glutamate-modulators such as MK-801, AP-7, RO25-6981, amantadine, memantine, CP-101,606 (traxoprodil) and riluzole were extensively studied in preclinical models (Dutta et al., 2015). Most of these agents fail to afford rapid and sustained antidepressant effects (Dutta et al., 2015; Preskorn et al., 2008; Zarate et al., 2004). Some promising results were observed with the low-trapping NMDA channel blocker AZD6765, which elicits rapid, but not sustained, antidepressant effects in treatment-resistant MDD patients (Zarate et al., 2013). However, the intracellular pathways involved in its effect are not established. Also, antidepressant-like effect of the NMDA receptor glycine-site partial agonist GLYX-13 requires AMPA receptor and mTOR activation, similar to ketamine (Lu et al., 2014). The antidepressant potential of GLYX-13 was confirmed in a clinical trial, and a fast (2 h) and sustained remission of depressive symptoms was observed without dissociative effects (Moskal et al., 2014; Preskorn et al., 2015). CP-101,606, a selective NR2B receptor antagonist, produced symptoms' remission by day 5 in depressed patients unresponsive to paroxetine (Preskorn et al., 2008). However, the intracellular pathways associated with this effect need to be elucidated in preclinical studies.

Metabotropic glutamate receptor modulators and AMPA receptor potentiators also represent interesting targets in the search for novel fast-acting antidepressant compounds. The blockade of presynaptic mGluR2/3 receptors regulates glutamate release and produces rapid behavioral responses that require activation of either AMPA receptors or mTOR signaling (Dwyer et al., 2012). Specifically, LY341495, an mGlu2/3 receptor antagonist, reduced the time required for antidepressants to exert their effects by a mechanism dependent on stimulation and expression of AMPA receptors in prefrontal cortex (Matrisciano et al., 2005). Moreover, preclinical studies have shown that AMPA potentiators LY392098 and LY451616 exhibit antidepressant effects associated with hippocampal increases on BDNF and progenitor cell proliferation. Also, the AMPAkine Ampalex elicited a rapid antidepressant effect when compare to fluoxetine (Knapp et al., 2002). Sleep deprivation, which is capable of producing rapid antidepressant effects, has similar effects on AMPA-mediated plasticity, suggesting that rapid enhancement of synaptic plasticity might represent the final target for symptoms remission (Faraguna et al., 2008).

Despite similar properties of these compounds at NMDA neurotransmission, their inability to replicate the fast, robust and sustained antidepressant effect of ketamine may be due to doses, pharmacokinetic differences, and activation of different intracellular signaling pathways.

3. Anti-inflammatory agents for the management of MDD

Depressive symptoms are commonly observed in patients with inflammatory conditions (e.g. aging and obesity), inflammatory diseases (e.g. atherosclerosis, congestive heart failure and rheumatoid arthritis), and in patients undergoing cytokine immunotherapy (Capuron and Dantzer, 2003). The presence of asthma and arthritis was significantly higher in depressed individuals (odds ratio (OR)=1.53, 95% CI, 1.03–2.28; OR=1.95, 95% CI, 1.17–3.25, respectively). Heart attack and stroke were more prevalent in depressed patients when compared to controls (OR=3.76, 95% CI, 1.95–7.27; OR=2.83, 95% CI, 1.59–5.06, respectively) (Kim et al., 2015). Diabetes mellitus is also more prevalent in the depressed group (OR=1.65, 95% CI, 0.93–2.92) and a meta-

analysis of longitudinal studies demonstrated that obesity increases the risk for MDD (OR=1.55, 95% CI, 1.22–1.98) (Kim et al., 2015; Luppino et al., 2010). Notably, MDD is associated with peripheral increase on pro-inflammatory cytokines, such as tumor-necrosis factor-α (TNF-α) and interleukin-1β (Dowlati et al., 2009). Collectively, these data suggest that the relationship between MDD and inflammation is bidirectional and driven by immune deregulation.

Depressed patients also show increased plasma ratio of kynurenine to tryptophan as a consequence of excessive activation of the enzyme indoleamine 2,3-dioxygenase (IDO) by pro-inflammatory cytokines. IDO activation produces kynurenine that, in turn, may be metabolized by perivascular macrophages and microglia to generate neuroactive glutamatergic compounds, such as quinolinic acid, an NMDA receptor agonist, contributing to glutamatergic excitotoxicity (Dantzer and Walker, 2014). Therefore, anti-inflammatory agents modulating pro-inflammatory cytokines levels, IDO activity, microglial activation and consequently glutamatergic excitotoxicity may be promising agents for MDD treatment.

Several anti-inflammatory strategies, such as minocycline,

monoclonal antibodies (anti-TNF-α) and IDO inhibitor (1-methyl-tryptophan) produce robust antidepressant-like effects in preclinical models (Liu et al., 2015). Several studies have shown the effect of the nonsteroidal anti-inflammatory drugs (NSAIDs) acetylsalicylic acid and celecoxib as adjunctive antidepressant agents (Rosenblat et al., 2014). A meta-analysis exploring 14 randomized clinical trials concluded that NSAIDs and cytokine inhibitors reduce depressive symptoms as compared to placebo (Köhler et al., 2014). However, the best evidence available on the subject is for celecoxib. A recent meta-analysis showed that 4–6 weeks of treatment with celecoxib was associated with higher response (OR=6.6, 95% CI, 2.5–17.0) and higher remission rates (OR=6.6, 95% CI, 2.7–15.9) in medicated MDD patients (Faridhosseini et al., 2014). It is still not established if these benefits are limited to patients with increased peripheral inflammatory markers and there are no data to support the use of celecoxib or other NSAIDs in antidepressant-resistant patients.

Preclinical studies show that depressive behavior associated with inflammatory conditions involves increased glutamate levels in prefrontal cortex of mice (Martín-de-Saavedra et al., 2013). In addition, increased levels of pro-inflammatory cytokines and

Fig. 1. Potential strategies for the management of MDD targeting glutamatergic modulation and inflammation. Several studies have suggested that the ketamine and some glutamatergic agents, including ascorbic acid, creatine, zinc, guanosine, as well as mGluR2/3 antagonist LY341495, and NMDA receptor glycine site functional partial agonist GLYX-13 which modulate the glutamatergic system may cause antidepressant effects. These compounds may cause stimulation of mTOR activity and synthesis of synaptic proteins (such as PSD-95 and GluA1), leading to synaptogenesis. This mechanism is particularly well established for ketamine and remains to be investigated for the other mentioned glutamatergic modulators. Furthermore, proinflammatory cytokines induce IDO activation, which in turn increase the levels of kynurenine (KYN) and its toxic metabolite quinolinic acid, an NMDA receptor agonist that mediates excitotoxicity. Ketamine and other anti-inflammatory drugs may decrease the levels of pro-inflammatory cytokines, KYN and its metabolites. IDO inhibitors decrease KYN levels and microglial activation and exert antidepressant effects. Akt=Protein kinase B; BDNF=brain-derived neurotrophic factor; ERK=extracellular signal-regulated kinase; HAAO=3-hydroxyanthranilate 3,4-dioxygenase; IDO=indoleamine 2,3-dioxygenase; KY-NU=kynureninase; KMO=kynurenine 3-monooxygenase; MEK = mitogen-activated protein kinase kinase; mTORC1=mammalian target of rapamycin complex 1; NMDAR=N-methyl-D-aspartate receptor; PI3K=phosphoinositide 3 kinase; TrkB=tropomyosin receptor kinase B.

quinolinic acid in cerebrospinal fluid were reported in medication-free suicide attempters (Erhardt et al., 2013). It is proposed that glutamatergic modulators may be useful for treating MDD associated with inflammatory dysfunctions. Interestingly, ketamine abrogated anhedonic behavior induced by lipopolysaccharide administration (a model of neuroinflammation) via AMPA receptor activation (Walker et al., 2013). Furthermore, ketamine presents anti-inflammatory properties associated with antidepressant-like profile in rodents submitted to maternal deprivation (Réus et al., 2015). Therefore, glutamatergic modulators may reduce neuroinflammation, contributing to remission of depressive symptoms.

4. General conclusions and future perspectives

Drugs targeting the glutamatergic system that elicit safe and fast-acting antidepressant action as well as anti-inflammatory agents might represent promising strategies for MDD (Fig. 1). Regarding this issue, studies conducted by our and other laboratories shed light on the possibility that glutamatergic modulators such as magnesium, zinc, guanosine, creatine, ascorbic acid, as well as GLYX-13 and LY341495 should be further investigated for efficacy in MDD treatment. Of note, the search for fast-acting antidepressants able to counteract neuroinflammation and increase neuroplasticity and cell survival might lead to a significant advance in antidepressant field. However, much work remains to be done to completely understand the mechanisms underlying the antidepressant effects of ketamine and other compounds capable of modulating glutamatergic transmission and activating mTOR signaling. Future challenge will be determining whether these rapid-acting compounds can be used for routine treatment in MDD and establish how to maintain prolonged therapeutic effects. However, it should be noted that mTOR signaling stimulation may have some risk since it is implicated in disease states in which growth is deregulated and homeostasis is compromised, such as cancer, metabolic diseases and aging (Zoncu et al., 2011). To address these issues preclinical and clinical research need to work together to achieve advances in understanding the different behavioral, biochemical and genetic dimensions that integrate this complex disorder.

Acknowledgments

References

Abdallah, C.G., Sanacora, G., Duman, R.S., Krystal, J.H., 2015. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu. Rev. Med. 66, 509–523.

Allen, P.J., 2012. Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value? Neurosci. Biobehav. Rev. 36, 1442–1462.

Amr, M., El-Mogy, A., Shams, T., Vieira, K., Lakhan, S.E., 2013. Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. Nutr. J. 9, 12–31.

Barragán-Rodríguez, L., Rodríguez-Morán, M., Guerrero-Romero, F., 2008. Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial. Magnes. Res. 21, 218–223.

Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., Krystal, J.H., 2000. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351–354.

Bettio, L.E., Cunha, M.P., Budni, J., Pazini, F.L., Oliveira, A., Colla, A.R., Rodrigues, A.L.,

2012. Guanosine produces an antidepressant-like effect through the modulation of NMDA receptors, nitric oxide-cGMP and PI3K/mTOR pathways. Behav. Brain Res. 234, 137–148.

Capuron, L., Dantzer, R., 2003. Cytokines and depression: the need for a new paradigm. Brain Behav. Immun. 17, 119–124.

Cardoso, C.C., Lobato, K.R., Binfaré, R.W., Ferreira, P.K., Rosa, A.O., Santos, A.R., Rodrigues, A.L., 2009. Evidence for the involvement of the monoaminergic system in the antidepressant-like effect of magnesium. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 235–242.

Castrén, E., Rantamaki, T., 2010. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev. Neurobiol. 70, 289–297.

Cunha, M.P., Pazini, F.L., Ludka, F.K., Rosa, J.M., Oliveira, Á., Budni, J., Ramos-Hryb, A.B., Lieberknecht, V., Bettio, L.E., Martín-de-Saavedra, M.D., López, M.G., Tasca, C.I., Rodrigues, A.L., 2015a. The modulation of NMDA receptors and L-arginine/nitric oxide pathway is implicated in the anti-immobility effect of creatine in the tail suspension test. Amino Acids 47, 795–811.

Cunha, M.P., Budni, J., Ludka, F.K., Pazini, F.L., Rosa, J.M., Oliveira, Á., Lopes, M.W., Tasca, C.I., Leal, R.B., Rodrigues, A.L., 2015b. Involvement of PI3K/Akt signaling pathway and its downstream intracellular targets in the antidepressant-like effect of creatine. Mol. Neurobiol. 10.1007/s12035-015-9192-4 (in press)

Dantzer, R., Walker, A.K., 2014. Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression? J. Neural. Transm. 121, 925–932.

Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctot, K.L., 2009. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446–457.

Dutta, A., McKie, S., Deakin, J.F., 2015. Ketamine and other potential glutamate antidepressants. Psychiatry Res. 225, 1–13.

Dwyer, J.M., Lepack, A.E., Duman, R.S., 2012. mTOR activation is required for the antidepressant effects of mGluR2/3 blockade. Int. J. Neuropsychopharmacol. 15, 429–434.

Erhardt, S., Lim, C.K., Linderholm, K.R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T.T., Träskman-Bendz, L., Guillemin, G.J., Brundin, L., 2013. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 38, 743–752.

Faraguna, U., Vyazovskiy, V.V., Nelson, A.B., Tononi, G., Cirelli, C., 2008. A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. J. Neurosci. 28, 4088–4095.

Faridhosseini, F., Sadeghi, R., Farid, L., Pourgholami, M., 2014. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum. Psychopharmacol. 29, 216–223.

Kim, W.K., Shin, D., Song, W.O., 2015. Depression and its comorbid conditions more serious in women than in men in the United States depression and its comorbid conditions more serious in women than in men in the United States. J Womens Health 10.1089/jwh.2014.4919 (in press).

Knapp, R.J., Goldenberg, R., Shuck, C., Cecil, A., Watkins, J., Miller, C., Crites, G., Malatynska, E., 2002. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur. J. Pharmacol. 440, 27–35.

Köhler, O., Benros, M.E., Nordentoft, M., Farkouh, M.E., Iyengar, R.L., Mors, O., Krogh, J., 2014. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71, 1381–1391.

Lai, J., Moxey, A., Nowak, G., Vashum, K., Bailey, K., McEvoy, M., 2012. The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J. Affect. Disord. 136, 31–39.

Lanquillon, S., Krieg, J.C., Bening-Abu-Shach, U., Vedder, H., 2000. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22, 370–379.

Li, N., Lee, B.Y., Liu, R.J., Banasr, M., Dwyer, J., Iwata, M., Li, X.Y., 2010. Aghajanian G, Duman RS. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959–964.

Liu, Y.N., Peng, Y.L., Liu, L., Wu, T.Y., Zhang, Y., Lian, Y.J., Yang, Y.J., Kelley, K.W., Jiang, C.L., Wang, Y.X., 2015. TNFα mediates stress-induced depression by upregulating indoleamine 2,3-dioxygenase in a mouse model of unpredictable chronic mild stress. Eur. Cytokine Netw. 26, 15–25.

Lu, Y., Wang, C., Xue, Z., Li, C., Zhang, J., Zhao, X., Liu, A., Wang, Q., Zhou, W., 2014. PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13. Int. J. Neuropsychopharmacol. 18, 1–12.

Luppino, F.S., de Wit, L.M., Bouvy, P.F., Stijnen, T., Cuijpers, P., Penninx, B.W., Zitman, F.G., 2010. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch. Gen. Psychiatry 67, 220–229.

Manosso, L.M., Moretti, M., Ribeiro, C.M., Gonçalves, F.M., Leal, R.B., Rodrigues, A.L., 2015. Antidepressant-like effect of zinc is dependent on signaling pathways implicated in BDNF modulation. Prog. Neuropsychopharmacol. Biol. Psychiatry 59, 59–67.

Martín-de-Saavedra, M.D., Budni, J., Cunha, M.P., Gómez-Rangel, V., Lorrio, S., Del Barrio, L., Lastres-Becker, I., Parada, E., Tordera, R.M., Rodrigues, A.L., Cuadrado, A., López, M.G., 2013. Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. Psychoneuroendocrinology 38, 2010–2022.

Matrisciano, F., Scaccianoce, S., Del Bianco, P., Panaccione, I., Canudas, A.M., Battaglia, G., Riozzi, B., Ngomba, R.T., Molinaro, G., Tatarelli, R., Melchiorri, D., Nicoletti, F., 2005. Metabotropic glutamate receptors and neuroadaptation to antidepressants: imipramine-induced down-regulation of beta-adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands. J.

Neurochem. 93, 1345–1452.

Moretti, M., Freitas, A.E., Budni, J., Fernandes, S.C., Balen, G.O., Rodrigues, A.L., 2011. Involvement of nitric oxide-cGMP pathway in the antidepressant-like effect of ascorbic acid in the tail suspension test. Behav. Brain Res. 225, 328–333.

Moretti, M., Budni, J., Freitas, A.E., Rosa, P.B., Rodrigues, A.L., 2014. Antidepressant-like effect of ascorbic acid is associated with the modulation of mammalian target of rapamycin pathway. J. Psychiatr. Res. 48, 16–24.

Moskal, J.R., Burch, R., Burgdorf, J.S., Kroes, R.A., Stanton, P.K., Disterhoft, J.F., Leander, J.D., 2014. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert. Opin. Investig. Drugs 23, 243–254.

Murck, H., 2013. Ketamine, magnesium and major depression – from pharmacology to pathophysiology and back. J. Psychiatr. Res. 47, 955–965.

Neis, V.B., Moretti, M., Manosso, L.M., Lopes, M.W., Leal, R.B., Rodrigues, A.L., 2015. Agmatine enhances antidepressant potency of MK-801 and conventional antidepressants in mice. Pharmacol. Biochem. Behav. 130, 9–14.

Papakostas, G.I., Ionescu, D.F., 2015. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol. Psychiatry. 20, 1142–1150.

Preskorn, S.H., Baker, B., Kolluri, S., Menniti, F.S., Krams, M., Landen, J.W., 2008. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 28, 631–637.

Preskorn, S., Macaluso, M., Mehra, D.O., Zammit, G., Moskal, J.R., Burch, R.M., 2015. GLYX-13 Clinical study group. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J. Psychiatr. Pract. 21, 140–149.

Réus, G.Z., Nacif, M.P., Abelaira, H.M., Tomaz, D.B., dos Santos, M.A., Carlessi, A.S., da Luz, J.R., Gonçalves, R.C., Vuolo, F., Dal-Pizzol, F., Carvalho, A.F., Quevedo, J., 2015. Ketamine ameliorates depressive-like behaviors and immune alterations in adult rats following maternal deprivation. Neurosci. Lett. 584, 83–87.

Rosenblat, J.D., Cha, D.S., Mansur, R.B., McIntyre, R.S., 2014. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 53, 23–34.

Sanacora, G., Treccani, G., Popoli, M., 2012. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62, 63–77.

Schildkraut, J.J., 1965. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 122, 509–522.

Shopsin, B., 2013. The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study. Acta Neuropsychiatr. 25, 113–118.

Skolnick, P., 1999. Antidepressants for the new millennium. Eur. J. Pharmacol. 375, 31–40.

Sen, S., Duman, R., Sanacora, G., 2008. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 64, 527–532.

Trullas, R., Skolnick, P., 1990. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185, 1–10.

Walker, A.K., Budac, D.P., Bisulco, S., Lee, A.W., Smith, R.A., Beenders, B., Kelley, K.W., Dantzer, R., 2013. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 38, 1609–1616.

Zarate Jr., C.A., Payne, J.L., Quiroz, J., Sporn, J., Denicoff, K.K., Luckenbaugh, D., Charney, D.S., Manji, H.K., 2004. An open-label trial of riluzole in patients with treatment-resistant major depression. Am. J. Psychiatry 161, 171–174.

Zarate Jr., C.A., Mathews, D., Ibrahim, L., Chaves, J.F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N.E., Smith, M.A., Luckenbaugh, D.A., 2013. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol. Psychiatry 74, 257–264.

Zoncu, R., Efeyan, A., Sabatini, D.M., 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell. Biol. 12, 21–35.